FDA Warning Letter Weakens Shares of Akorn
Quick Picks - This week, the FDA posted a warning letter to Akorn, Inc (NASDAQ:AKRX) dated October 2, warning the company that it is manufacturing an unapproved drug, … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
AMRN To Fall Further Given No Vascepa NCE Decision This Month
Long Ideas - In an 8K released on Wednesday morning, Amarin Corp. (NASDAQ:AMRN) revealed that the FDA still has not made a decision regarding Vascepa’s New Chemical Entity … Continue Reading
Read nowILMN To Trade Up On Positive Business Trends, Potential 3Q EPS Upside
Long Ideas - Notwithstanding the take-out chatter on Illumina (NASDAQ:ILMN), with the potential that Roche (OTC:RHHBY) may take another run at the company for $60 a share (read … Continue Reading
Read nowELN Under Pressure On ECTRIMS Meeting & Valuation
Long Ideas - With Biogen-Idec’s (NASDAQ:BIIB) new multiple sclerosis (MS) treatment, BG-12, approaching a decision by the FDA (PDUFA date December 28th), enthusiasm in the medical community is … Continue Reading
Read nowEli Lilly Strong after Solanezumab Demonstrates Slowing of Cognitive Decline
Long Ideas - Following news that Elan’s (NASDAQ:ELN) developmental Alzheimer’s treatment, bapineuzumab, failed a Phase III trial in August and was subsequently discontinued, PropThink advised a position in … Continue Reading
Read nowQCOR Posts Positive Script Trends For Acthar; Analyst Comes Back Around
Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) announced prescription trend data this morning for its primary revenue driver, H.P. Acthar Gel (Acthar), and the news is positive, sending the … Continue Reading
Read nowAnticipation of NDA Acceptance Driving Delcath Shares; Decision Expected Friday
Long Ideas - Delcath Systems (NADSAQ:DCTH) continues to trade well-above average volume Tuesday, ahead of the FDA’s decision on the company’s recently submitted New Drug Application (NDA) for … Continue Reading
Read now